SCHEMBL2076784

SCHEMBL2076784

CC(C)(C)C(=O)Nc1c(C(=O)c2ccc(F)cc2F)ccnc1-c1c(Cl)cccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 4/20 0.42
▸ EGFR P00533 2/20 0.38
▸ KDR P35968 1/20 0.38
▸ MAPT P10636 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ PDK1 Q15118 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ PDK3 Q15120 1/20 0.36
▸ PDK4 Q16654 1/20 0.36
▸ MAPK13 O15264 1/20 0.35
▸ MAPK12 P53778 1/20 0.35
▸ MAPK11 Q15759 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CHRNA7 P36544 1/20 0.35
▸ CNR2 P34972 1/20 0.35
▸ SYK P43405 1/20 0.35
▸ LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2829217 0.94 EGFR (0.39) MAPK14EGFRKDRMAPTMEN1
SCHEMBL4078010 0.91 MAPK14 (0.40) MAPK14MAPTMEN1KMT2AMAPK13
SCHEMBL2079338 0.89 MAPK14 (0.43) MAPK14MEN1KMT2AMAPK13MAPK12
SCHEMBL2825730 0.89 MAPK13 (0.38) MAPK14EGFRKDRMAPTMAPK13
SCHEMBL2828600 0.84 RORB (0.44) MAPK14KDRMAPTMEN1KMT2A
SCHEMBL2832374 0.82 RORB (0.41) MAPK14MAPTMEN1KMT2APDK1
SCHEMBL2826952 0.82 MAPK14 (0.44) MAPK14MAPTMEN1KMT2AMAPK13
SCHEMBL1642060 0.79 MAPK14 (0.59) MAPK14MAPK13MAPK12MAPK11POLB
SCHEMBL2081557 0.75 CCNT1 (0.34) MAPK14EGFRKDRMAPTMEN1
SCHEMBL13321787 0.72 CCNT1 (0.35) EGFRKDRMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906530-B2 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2011-03-15 — — US disclosed
US-20100227881-A1 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-09 — — US disclosed
EP-2049537-A1 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS Laboratorios Almirall, S.A. (ES) 2009-04-22 — — EP disclosed
WO-2008017461-A1 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS LABORATORIOS ALMIRALL, S.A. (ES) 2008-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227881-A1 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS MAPK1, MAPK7, MAPKAPK2 MAPK14 23/4885EGFR 1634/4885KDR 2395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback